Short answer
Cogent Biosciences, Inc. (COGT) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results for three months ended March 31, 2026.
Cogent Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for three months ended March 31, 2026
- Press release contains financial results and accompanying management commentary
- Exhibit 99.1 provides the substantive earnings details for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 net loss $97.4M vs $72.0M; operating expenses increased to $103.6M from $74.9M
- Cash, equivalents and marketable securities $866.4M, supporting operations and planned commercialization into 2028
- FDA accepted NonAdvSM NDA with December 30, 2026 PDUFA action date
- GIST NDA submitted under FDA’s Real-Time Oncology Review after positive Phase 3 PEAK results
- Dual bezuclastinib launches targeted for second half 2026, pending FDA approvals
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cogent Biosciences, Inc. 8-K filings
Get the next COGT 8-K as it lands
Follow COGT for push alerts, or ask the research agent what this filing means.